{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"62.5"},{"groupId":"OG002","value":"33.3"},{"groupId":"OG003","value":"63.2"},{"groupId":"OG004","value":"80.0"},{"groupId":"OG005","value":"60.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"10"}],"units":"Participants"}],"description":"Participants who achieved a platelet count \\>=50 Gi/L at least once between Day 8 and Day 43 (first 6 weeks of Part 2) in the absense of rescue treatment were reported. A 95% confidence interval was calculated by the exact binomial method.","groups":[{"description":"Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.","id":"OG000","title":"Part 2 (Randomized Period) Cohort 1-Placebo"},{"description":"Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG001","title":"Part 2 (Randomized Period) Cohort 1- Eltrombopag"},{"description":"Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.","id":"OG002","title":"Part 2 (Randomized Period) Cohort 2-Placebo"},{"description":"Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \\<27 kg received 25 mg QD and participants with a weight of \\>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \\<27 kg received 12.5 mg QD and participants with a weight of \\>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG003","title":"Part 2 (Randomized Period) Cohort 2-Eltrombopag"},{"description":"Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.","id":"OG004","title":"Part 2 (Randomized Period) Cohort 3-Placebo"},{"description":"Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG005","title":"Part 2 (Randomized Period) Cohort 3- Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat (ITT) Population: all enrolled participants during Part 2. The ITT Population was the primary population used for assessing efficacy. Only evaluable participants were considered for analysis where participants with a Baseline platelet count \\>10Gi/L was considered as evaluable.","reportingStatus":"POSTED","timeFrame":"From Day 8 up to Day 43 of Part 2","title":"Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}